Published in J Vasc Surg on April 01, 2006
Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol (2013) 1.38
Validation of the Society for Vascular Surgery's objective performance goals for critical limb ischemia in everyday vascular surgery practice. J Vasc Surg (2011) 1.16
A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv (2012) 1.15
Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg (2011) 1.08
Outcomes of endovascular lower extremity interventions depend more on indication than physician specialty. J Vasc Surg (2013) 1.08
The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. J Transl Med (2011) 1.04
Critical limb ischemia. Curr Treat Options Cardiovasc Med (2010) 0.88
Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia. Am Heart J (2012) 0.88
Peripheral arterial disease. BMJ Clin Evid (2011) 0.77
Fourth Asian PAD Workshop. Ann Vasc Dis (2013) 0.77
Geriatric Nutritional Risk Index (GNRI) Independently Predicts Amputation Inchronic Criticallimb Ischemia (CLI). PLoS One (2016) 0.76
Proceedings from the Society of Interventional Radiology research consensus panel on critical limb ischemia. J Vasc Interv Radiol (2013) 0.76
Therapeutic effect of liposomal prostaglandin E1 in acute lower limb ischemia as an adjuvant to hybrid procedures. Exp Ther Med (2013) 0.75
Treatment of refractory cutaneous ulcers with mixed sheets consisting of peripheral blood mononuclear cells and fibroblasts. Sci Rep (2016) 0.75
Infrainguinal open reconstruction: a review of surgical considerations and expected outcomes. Vasc Health Risk Manag (2017) 0.75
Peripheral arterial disease. BMJ Clin Evid (2007) 0.75
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology (2010) 7.30
Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA (2009) 5.66
Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology (2011) 4.61
Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation (2012) 3.39
Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet (2011) 2.88
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg (2010) 2.52
Exercise training for claudication. N Engl J Med (2002) 2.26
Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain (2012) 2.18
Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension (2004) 2.17
Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation (2003) 1.93
Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol (2006) 1.92
Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation (2004) 1.65
The actin-interacting protein AIP1 is essential for actin organization and plant development. Curr Biol (2004) 1.60
Utility and barriers to performance of the ankle-brachial index in primary care practice. Vasc Med (2004) 1.57
Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol (2003) 1.54
Cryoplasty for the treatment of femoropopliteal arterial disease: results of a prospective, multicenter registry. J Vasc Interv Radiol (2005) 1.51
Functional outcome in a contemporary series of major lower extremity amputations. J Vasc Surg (2003) 1.51
A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life. J Am Coll Cardiol (2008) 1.50
The risk of major elective vascular surgical procedures in patients with end-stage renal disease. Ann Surg (2013) 1.49
Aspirin for prevention of cardiovascular events. BMJ (2008) 1.49
Inflammation in peripheral artery disease. Circulation (2010) 1.47
Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting. Pharmacotherapy (2012) 1.46
Managing abnormal blood lipids: a collaborative approach. Circulation (2005) 1.44
Clinical outcomes using aggressive approach to anatomic screening and endovascular revascularization in a veterans affairs population with critical limb ischemia. Catheter Cardiovasc Interv (2009) 1.38
The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. Vasc Med (2008) 1.37
Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J (2011) 1.35
Sharing Data from Cardiovascular Clinical Trials - A Proposal. N Engl J Med (2016) 1.34
Objective assessment of temporal bone drilling skills. Ann Otol Rhinol Laryngol (2007) 1.34
Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. N Engl J Med (2015) 1.34
The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care (2004) 1.31
Increased expression of the human Ca2+-activated Cl- channel 1 (CaCC1) gene in the asthmatic airway. Am J Respir Crit Care Med (2002) 1.29
Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation (2003) 1.28
Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc (2002) 1.26
Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation (2011) 1.25
Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies. Vasc Med (2006) 1.24
Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol (2007) 1.22
Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med (2002) 1.22
A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. Circulation (2012) 1.19
Ultrasound-accelerated thrombolysis for the treatment of deep vein thrombosis: initial clinical experience. J Vasc Interv Radiol (2008) 1.18
Cardiovascular disease mortality in Hispanics and non-Hispanic whites. Am J Epidemiol (2002) 1.17
Adrenal schwannoma: CT and MRI findings. Radiat Med (2007) 1.16
Impaired muscle oxygen use at onset of exercise in peripheral arterial disease. J Vasc Surg (2004) 1.16
Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease. Vasc Med (2007) 1.13
Combined species identification, genotyping, and drug resistance detection of Mycobacterium tuberculosis cultures by MLPA on a bead-based array. PLoS One (2012) 1.12
Life threatening complications after partially treated mastoiditis. BMJ (2003) 1.10
Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients. Arterioscler Thromb Vasc Biol (2011) 1.10
Pre-existing isoniazid resistance, but not the genotype of Mycobacterium tuberculosis drives rifampicin resistance codon preference in vitro. PLoS One (2012) 1.10
Wound healing and functional outcomes after infrainguinal bypass with reversed saphenous vein for critical limb ischemia. J Vasc Surg (2006) 1.09
Medical therapy in peripheral artery disease. Circulation (2012) 1.08
New diffusion metrics for spondylotic myelopathy at an early clinical stage. Eur Radiol (2012) 1.07
Diffusional kurtosis imaging of normal-appearing white matter in multiple sclerosis: preliminary clinical experience. Jpn J Radiol (2012) 1.05
Skeletal muscle StO2 kinetics are slowed during low work rate calf exercise in peripheral arterial disease. Eur J Appl Physiol (2007) 1.04
Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina (2014) 1.04
Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease. J Appl Physiol (1985) (2011) 1.03
Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpoint discussion. Vasc Med (2004) 1.03
Improving the FDA's advisory committee process. J Clin Pharmacol (2011) 1.01
Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases. Circulation (2008) 1.00
Decreased expression of antioxidant enzymes and increased expression of chemokines in COPD lung. Pulm Pharmacol Ther (2006) 1.00
A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med (2010) 0.99
Evaluating effects of method of administration on Walking Impairment Questionnaire. J Vasc Surg (2003) 0.99
Diffusional kurtosis imaging of cingulate fibers in Parkinson disease: comparison with conventional diffusion tensor imaging. Magn Reson Imaging (2013) 0.99
Assessment of functional status and quality of life in claudication. J Vasc Surg (2011) 0.98
Peripheral arterial disease rehabilitation: a review. J Cardiopulm Rehabil (2003) 0.97
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood (2010) 0.97
A case of incarcerated lesser sac hernia protruding simultaneously through both the gastrocolic and gastrohepatic omenta. Radiat Med (2002) 0.95
Misleading conclusion. Int J Tuberc Lung Dis (2010) 0.94
Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training. Vasc Med (2012) 0.94
Cryoplasty for the treatment of femoropopliteal arterial disease: extended follow-up results. J Endovasc Ther (2006) 0.94
The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol (2006) 0.93
Patterns of artery disease in 450 patients undergoing revascularization for critical limb ischemia: implications for clinical trial design. J Vasc Surg (2008) 0.92
Fibrates in the treatment of dyslipidemias--time for a reassessment. N Engl J Med (2011) 0.92
Is revascularization and limb salvage always the best treatment for critical limb ischemia? J Vasc Surg (2003) 0.92
Pulmonary VO2 dynamics during treadmill and arm exercise in peripheral arterial disease. J Appl Physiol (1985) (2004) 0.91
Clinical and demographic predictors of exercise capacity in end-stage renal disease. Am J Kidney Dis (2002) 0.90
Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk. Clin Pharmacol Ther (2006) 0.90
Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. J Vasc Surg (2007) 0.89
Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia. Am Heart J (2012) 0.88
Aspirin in primary prevention: can we individualize care? Cardiovasc Diagn Ther (2012) 0.88
White matter alteration in metabolic syndrome: diffusion tensor analysis. Diabetes Care (2012) 0.88
Role of eosinophil chemotactic factor by T lymphocytes on airway hyperresponsiveness in a murine model of allergic asthma. Am J Respir Cell Mol Biol (2006) 0.87
Progression of asymptomatic peripheral artery disease over 1 year. Vasc Med (2012) 0.87
Posterior hypoperfusion in Parkinson's disease with and without dementia measured with arterial spin labeling MRI. J Magn Reson Imaging (2011) 0.87
Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract (2013) 0.87
TASC II section F on revascularization in PAD. J Endovasc Ther (2007) 0.86
Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial. J Vasc Interv Radiol (2004) 0.86
Cryoplasty therapy for limb salvage in patients with critical limb ischemia. J Endovasc Ther (2007) 0.86
Increased human Ca²⁺-activated Cl⁻ channel 1 expression and mucus overproduction in airway epithelia of smokers and chronic obstructive pulmonary disease patients. Respir Res (2012) 0.85
Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial. Vasc Med (2004) 0.85
The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. Contemp Clin Trials (2009) 0.85
Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin. Arthritis Res Ther (2010) 0.84
Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice. Brain Res (2009) 0.83
Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.83